Company: CERO
Filing Date: 2025-01-21
Form Type: S-1/A
Source: 0001213900-25-004742
Chunk: 16

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-01-21
Form: S-1/A
Chunk 16
---
2025, we issued 408,683 shares of common stock for net proceeds of $2,273,794 pursuant to the New Keystone Purchase Agreement. As of the date of this prospectus, we have issued and sold 644,966 shares of Common Stock for aggregate proceeds of $5,902,814 under the Keystone Equity Financings (the Old Keystone Purchase Agreement and New Keyston Purchase Agreement). We do not have a right to commence any sales of Common Stock to Keystone under the New Keystone Purchase Agreement until the time when all of the conditions to our right to commence sales of Common Stock to Keystone set forth in the New Keystone Purchase Agreement have been satisfied, including the effectiveness of the registration statement of which this prospectus forms a part. We will control the timing and amount of any sales of Common Stock to Keystone. Actual sales of shares of Common Stock to Keystone under the Keystone Purchase Agreements will depend on a variety of factors to be determined by us from time to time, including, among others, market conditions, the trading price of the Common Stock and determinations by us as to the appropriate sources of funding and our operations. Concurrent with the execution of the New Keystone Purchase Agreement, we entered into the New Keystone Registration Rights Agreement, pursuant to which we agreed to provide Keystone with customary registration rights related to the shares issued under the New Keystone Purchase Agreement. 1 Third PIPE Financing On September 25, 2024, we consummated a private placement of 2,853 shares of Series C Preferred Stock and 81,752 Series C Warrants pursuant to the Third Securities Purchase Agreement, by and among us and certain PIPE Investors for aggregate cash proceeds of approximately $1.25 million. In connection with the Third PIPE Financing, we entered into the Third PIPE Registration Rights Agreement with the PIPE Investors. The terms of the Third PIPE Registration Rights Agreement require us to register the number of shares of Common Stock equal to the sum of (i) 250% of the maximum number of Common Stock issuable upon conversion of the Series C Preferred Stock (assuming for purposes hereof that (x) the Series C Preferred Stock is convertible at the Alternate Conversion Price (as defined in the Series C Certificate of Designations) assuming an Alternate Conversion Date (as defined in the Series C Certificate of Designations) of such date of determination, and (y) any such conversion shall not take into account any limitations on the conversion of the Series C Preferred Stock set forth in the Series C Certificate of Designations) and (ii) the maximum